Swiss pharmaceutical company, Novartis, has given a positive assessment of the battle it is facing to produce more blockbuster drugs and overcome the so-called “patent cliff”.
Over the past few years, many of Novartis’ key drugs have lost exclusivity in major markets and are coming up against tough generic competition. However, the pharma company has announced it is confident it can retain its success and growth in the future, with over 139 projects currently in clinical development. These projects include more than 73 new molecular entities, spread across a wide area of diseases, including cancer, heart and respiratory treatments. (...) - by Hannah Blake, pharmaphorum, 8th November 2012